The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Autoimmun Rev. 2024 May;23(5):103533. doi: 10.1016/j.autrev.2024.103533. Epub 2024 Mar 22.

Abstract

Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific endpoints focused on SpA are not available in the IBD setting. To address this important clinical topic, the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and the Italian Society of Rheumatology (SIR) jointly planned to draw updated therapeutic recommendations for IBD-associated SpA using a pseudo-Delphi method. This document presents the official recommendations of IG-IBD and SIR on the management of IBD-associated SpA in the form of 34 statements and 4 therapeutic algorithms. It is intended to be a reference guide for gastroenterologists and rheumatologists dealing with IBD-associated SpA.

Keywords: Biologics; Crohn's disease; Small molecules; Spondyloarthritis; Ulcerative colitis.

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Consensus
  • Delphi Technique
  • Disease Management
  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / therapy
  • Italy
  • Rheumatology / standards
  • Societies, Medical / standards
  • Spondylarthritis* / complications
  • Spondylarthritis* / diagnosis
  • Spondylarthritis* / therapy